Abstract |
This study was to investigate whether the expressions of DNA repair genes ERCC1 (excision repair cross complementing 1), RRM1 ( ribonucleotide reductase subunit M1) and BRCA1 ( breast cancer 1) affected clinical outcome in patients with NSCLC. Patients with stage IIIb/IV NSCLC were given platinum-based chemotherapy. Messenger RNA expression levels of ERCC1, BRCA1 and RRM1 were determined by real-time polymerase chain reaction with TaqMan probes in the tumor. The relationship between these three genes with chemoresponse and overall survival was analyzed in this study. Eighty-five patients (median age 59, range 30-78) were enrolled into the study. Median overall survival (OS) was 13 months (range 10.8-15.2). Time to progression ( TTP) was 6.1 months (range 5.5-6.7). Patients with low ERCC1 expression benefited more from a platinum-containing regimen (P=0.094). Patients with low RRM1 expression benefited more from a gemcitabine-containing regimen. Patients with high BRCA1 expression benefited more from an anti- tubulin-containing regimen (P=0.046). Partial response rate was 42.4%. A statistically significant difference in OS was seen in patients with low ERCC1 levels compared to patients with high ERCC1 ones. (16.5 vs. 10.0 months, P=0.045). A significant relationship was observed between the expression of ERCC1 and BRCA1 and TTP (6.5 vs. 5.1 months, P=0.001, 5.2 vs. 6.5, P=0.019, respectively). High expression of BRCA1 was associated with better survival in the anti- tubulin-containing regimen subgroup (8.7 vs. 13.0, P=0.035). ERCC1, RRM1 and BRCA1 are promising predictive and prognostic biomarkers in advanced non-small cell lung cancer.
|
Authors | Chunxia Su, Songwen Zhou, Ling Zhang, Shengxiang Ren, Jianfang Xu, Jie Zhang, Meijun Lv, Jie Zhang, Caicun Zhou |
Journal | Medical oncology (Northwood, London, England)
(Med Oncol)
Vol. 28
Issue 4
Pg. 1411-7
(Dec 2011)
ISSN: 1559-131X [Electronic] United States |
PMID | 20467918
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- DNA-Binding Proteins
- RNA, Messenger
- Tumor Suppressor Proteins
- RRM1 protein, human
- Ribonucleoside Diphosphate Reductase
- BRAP protein, human
- Ubiquitin-Protein Ligases
- ERCC1 protein, human
- Endonucleases
|
Topics |
- Adult
- Aged
- Biomarkers, Tumor
(analysis)
- Carcinoma, Non-Small-Cell Lung
(genetics, mortality, pathology)
- DNA-Binding Proteins
(biosynthesis, genetics)
- Disease-Free Survival
- Endonucleases
(biosynthesis, genetics)
- Female
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms
(genetics, mortality, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Proportional Hazards Models
- RNA, Messenger
(analysis)
- Real-Time Polymerase Chain Reaction
- Ribonucleoside Diphosphate Reductase
- Treatment Outcome
- Tumor Suppressor Proteins
(biosynthesis, genetics)
- Ubiquitin-Protein Ligases
(biosynthesis, genetics)
|